



INSTITUTE OF HUMAN
VIROLOGY, NIGERIA

IHVN AT A GLANCE



Mentor Mothers play a vital role in preventing mother-to-child transmission of HIV. Through counseling, education, and support, they empower HIV-positive women to adhere to treatment, attend antenatal care and give birth to HIV-free babies. Together, they are building a future where every child is born healthy and free from HIV

The Institute of Human Virology, Nigeria (IHVN) is a non-governmental organisation established in 2004 to address the HIV/AIDS crisis in Nigeria by developing infrastructure for treatment, care, prevention, and support for people living with and affected by HIV/AIDS. IHVN has expanded its services to other infectious diseases like tuberculosis, malaria and non-infectious diseases, including cancers.

As a local organization, the Institute is structured to collaboratively develop and maintain linkages within and outside the country that support the Government of Nigeria's health sector strategic plans. IHVN's critical technical and funding partners include the Centers for Disease Control and Prevention (CDC), the Global Fund to Fight AIDS, Tuberculosis and Malaria.

ASPIRE: The ACTION to Sustain Precision and Integrated HIV Response towards Epidemic Control (ASPIRE) project is funded by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Prevention and Control (CDC). The project focuses on Nasarawa State, Rivers State, Katsina State, and the Federal Capital Territory (FCT). Amongst other areas, the ASPIRE project aims to reduce the mortality of people living with HIV (PLHIV) by providing services to know their HIV status and be linked to quality sustained treatment.

ASPIRE project provides the following services in the health facilities we support: HIV Testing Services (HTS), laboratory diagnosis and tracking of status of people living with HIV, Prevention of Mother-to-Child Transmission (PMTCT) of HIV, Anti-retroviral Treatment (ART) for adult and children (including pregnant women), care and support for people living with HIV/AIDS and people affected by HIV/AIDS, monitoring and evaluation of patients and program progress. As of June 2025, 610,595 patients received ARV drugs and treatment under this project.

RESEARCH and TRAINING: IHVN has established a center, the International Research Center of Excellence (IRCE) to promote public/private partnerships for quality health services, capacity building, and research in West Africa. IHVN, through IRCE, aims to foster collaboration between scientists both international and local healthcare providers, the government of Nigeria, and the communities it serves. IRCE has gradually expanded its research portfolio to include other infectious diseases such as Tuberculosis (TB), Malaria, viral Hepatitis, COVID-19, Monkey Pox, emerging viral infections, and other non-communicable diseases. This diversification

has allowed the center to contribute towards understanding and controlling infectious and non-infectious diseases. As of June 2025, 176,688 healthcare professionals have been trained in HIV, TB, and other areas.

Global Fund is a combined effort for tuberculosis (TB) and HIV and is pivotal for the transformation of TB and HIV programs. Under the guidance of the National AIDS and STDs Control Programme (NASCP), the National TB and Leprosy Control Programme (NTBLCP), and the National Agency for the Control of AIDS (NACA), this project aims to increase the identification of all forms of TB in both the private sector and the community. The Country Coordinating Mechanism for the Global Fund (CCM) has oversight functions to support the smooth implementation of the grant.

The GC7 project is focused on ensuring early diagnosis of TB and HIV and providing comprehensive care for affected individuals. It runs from January 2024 to December 2026 and will increase the provision of tuberculosis services in the community through public-private partnerships. Other grant objectives include expanding HIV testing for all pregnant women in communities and strengthening laboratories and supply chain management.

Since commencement of the project till June 2025, 207,409 people have been identified with tuberculosis and 2,243 HIV positive pregnant women have been reached and linked to care.

More than 300 community pharmacists and 4,500 private hospitals and faith-based clinics are now actively

screening, diagnosing and providing treatment for TB and HIV. Also, over 11,000 patent medicine vendors have been engaged and connected to TB diagnostic and treatment facilities. Over 6,000 traditional healers and birth attendants have been sensitized and integrated into community efforts for tuberculosis and HIV screening.

Prior to the GC7 project IHVN implemented the TB Public Private Mix Scale-up project as Principal Recipient from

January 2019 to March 2023. During that period, 175,867 TB cases were notified by non-national TB program providers. In addition, a Drug-resistant tuberculosis (DR-TB) program was implemented from June 2011 to December 2018 and it identified 9,036 drug-resistant tuberculosis cases and enrolled 6,515 drug-resistant tuberculosis patients for treatment. IHVN was also a sub-recipient to FHI 360, providing HTS, PMTCT, ART and TB/HIV services in ten states.

IHVN ACHIEVEMENTS FROM 2004 to June 2025

Project concluded in June 2019

	PEPFAR Funded (ACTION, ACTIONPlus, ACTION PlusUp, ACHIEVE, ASPIRE Projects)	Global Fund	TOTAL
 Individuals counseled, tested and received results	17,868,715	2,508,810	20,377,525
 Pregnant women counseled, tested and received results	4,393,191	1,550,279	5,943,470
 Pregnant women confirmed positive	121,148	21,679	142,827
 Pregnant women provided anti-retroviral prophylaxis	113,237	18,152	131,389
 Clients cumulatively enrolled in the HIV care program	712,774	104,837	817,611
 Clients cumulatively initiated on ART	610,595	99,262	709,857
 Pediatric clients cumulatively initiated (subset of ART above)	23,925	39,849	63,774
 Clients provided TB treatment	54,761	2,851	57,612
 Number of Orphans and Vulnerable Children (OVC) cared for	91,143	N/A	91,143
 Number of Services Delivery Points	ART:384	ART: 69	
	PMTCT:369	PMTCT: 347	
	TB:185	DR-TB:28	
	HTS:384	HTS:416	
Number of People Trained	176,688		

Leader in providing quality health services capacity building and research in West Africa



Institute of Human Virology, Nigeria



IHVNIgeria



ihvnigeria



info@ihvnigeria.org



www.ihvnigeria.org